Tags

Type your tag names separated by a space and hit enter

Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice.
J Appl Microbiol. 2008 Mar; 104(3):672-80.JA

Abstract

AIMS

The aim of the study was to evaluate the efficacy of probiotics on gut-derived sepsis caused by Pseudomonas aeruginosa in immunocompromised mice.

METHODS AND RESULTS

After oral inoculation of P. aeruginosa, mice were treated with cyclophosphamide to induce leucopenia and translocation of the intestinal P. aeruginosa into blood, thereby producing gut-derived sepsis. In this model, administration of 1 x 10(9) CFU of Bifidobacterium longum strain BB536 for 10 days significantly (P < 0.01) increased the survival rate compared with groups of mice administered either with Bifidobacterium breve strain ATCC 15700 or excipients contained in the probiotic bacterial powder. Administration of B. longum significantly decreased viable counts of P. aeruginosa in the liver and blood compared with other groups. Culture of intestinal contents revealed a significantly lower viable count of P. aeruginosa in the jejunum of B. longum-treated mice compared with other groups of mice. Furthermore, in vitro data demonstrated that B. longum possessed apparently higher adherent activity to Caco-2 cell monolayers and significantly suppressed the adherence of P. aeruginosa to the monolayers of cells compared with other groups.

CONCLUSION

Oral administration of B. longum protects mice against gut-derived sepsis caused by P. aeruginosa, and the effect may be due to interference of P. aeruginosa adherence to intestinal epithelial cells. SIGNIFICANCE AND IMPACT OF THIS STUDY: This study demonstrated that oral administration of B. longum BB536 is effective to protect against opportunistic infection with drug-resistant bacteria such as P. aeruginosa. The results suggest that probiotics may play an important role even in the immunocompromised patients.

Links

Aggregator Full Text

Authors+Show Affiliations

Matsumoto T
Department of Microbiology, Tokyo Medical University, Tokyo, Japan. tetsuya@tokyo-med.ac.jp
Ishikawa H
No affiliation info available
Tateda K
No affiliation info available
Yaeshima T
No affiliation info available
Ishibashi N
No affiliation info available
Yamaguchi K
No affiliation info available

MeSH

Administration, OralAnimalsAntibiosisBacterial AdhesionBifidobacteriumColony Count, MicrobialGastroenteritisGastrointestinal TractImmunocompromised HostMaleMiceMice, Inbred ICRProbioticsPseudomonas InfectionsPseudomonas aeruginosaSepsis

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17927741

Citation

Matsumoto, T, et al. "Oral Administration of Bifidobacterium Longum Prevents Gut-derived Pseudomonas Aeruginosa Sepsis in Mice." Journal of Applied Microbiology, vol. 104, no. 3, 2008, pp. 672-80.
Matsumoto T, Ishikawa H, Tateda K, et al. Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. J Appl Microbiol. 2008;104(3):672-80.
Matsumoto, T., Ishikawa, H., Tateda, K., Yaeshima, T., Ishibashi, N., & Yamaguchi, K. (2008). Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. Journal of Applied Microbiology, 104(3), 672-80.
Matsumoto T, et al. Oral Administration of Bifidobacterium Longum Prevents Gut-derived Pseudomonas Aeruginosa Sepsis in Mice. J Appl Microbiol. 2008;104(3):672-80. PubMed PMID: 17927741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. AU - Matsumoto,T, AU - Ishikawa,H, AU - Tateda,K, AU - Yaeshima,T, AU - Ishibashi,N, AU - Yamaguchi,K, Y1 - 2007/10/09/ PY - 2007/10/12/pubmed PY - 2008/5/24/medline PY - 2007/10/12/entrez SP - 672 EP - 80 JF - Journal of applied microbiology JO - J Appl Microbiol VL - 104 IS - 3 N2 - AIMS: The aim of the study was to evaluate the efficacy of probiotics on gut-derived sepsis caused by Pseudomonas aeruginosa in immunocompromised mice. METHODS AND RESULTS: After oral inoculation of P. aeruginosa, mice were treated with cyclophosphamide to induce leucopenia and translocation of the intestinal P. aeruginosa into blood, thereby producing gut-derived sepsis. In this model, administration of 1 x 10(9) CFU of Bifidobacterium longum strain BB536 for 10 days significantly (P < 0.01) increased the survival rate compared with groups of mice administered either with Bifidobacterium breve strain ATCC 15700 or excipients contained in the probiotic bacterial powder. Administration of B. longum significantly decreased viable counts of P. aeruginosa in the liver and blood compared with other groups. Culture of intestinal contents revealed a significantly lower viable count of P. aeruginosa in the jejunum of B. longum-treated mice compared with other groups of mice. Furthermore, in vitro data demonstrated that B. longum possessed apparently higher adherent activity to Caco-2 cell monolayers and significantly suppressed the adherence of P. aeruginosa to the monolayers of cells compared with other groups. CONCLUSION: Oral administration of B. longum protects mice against gut-derived sepsis caused by P. aeruginosa, and the effect may be due to interference of P. aeruginosa adherence to intestinal epithelial cells. SIGNIFICANCE AND IMPACT OF THIS STUDY: This study demonstrated that oral administration of B. longum BB536 is effective to protect against opportunistic infection with drug-resistant bacteria such as P. aeruginosa. The results suggest that probiotics may play an important role even in the immunocompromised patients. SN - 1365-2672 UR - https://www.unboundmedicine.com/medline/citation/17927741/Oral_administration_of_Bifidobacterium_longum_prevents_gut_derived_Pseudomonas_aeruginosa_sepsis_in_mice_ L2 - https://doi.org/10.1111/j.1365-2672.2007.03593.x DB - PRIME DP - Unbound Medicine ER -